This article was originally published in The Gray Sheet
Executive SummaryInitial public offering of 1.2 mil. shares at $5 each is outlined in a prospectus filed with the Securities and Exchange Commission. The San Diego development-stage firm plans to file a 510(k) with FDA in May for its first product, a disposable ambulatory infusion pump. Also in the pipeline is an ear and body-piercing device. Gross proceeds of $6 mil. are tabbed for sales and marketing activities, R&D, and working capital. The firm hopes to raise enough capital to qualify for listing on the Nasdaq small-cap market
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.